NCT06679959View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chronic Weight Management
Interventions
DRUG

ASC30 Injection, for subcutaneous use or placebo

Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use

Trial Locations (1)

78209

RECRUITING

Ascletis clinical site, San Antonio

All Listed Sponsors
lead

Ascletis Pharma (China) Co., Limited

INDUSTRY